Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
RCT 183 mild COVID-19 outpatients in Saudi Arabia, 91 treated with Nigella Sativa, showing lower hospitalization and faster recovery with treatment. 500mg Nigella Sativa oil (MARNYS Cuminmar) twice daily for 10 days. NCT04401202 (history)
risk of hospitalization, 74.7% lower, RR 0.25, p = 0.37, treatment 1 of 91 (1.1%), control 4 of 92 (4.3%), NNT 31.
risk of no recovery, 42.7% lower, RR 0.57, p < 0.001, treatment 34 of 91 (37.4%), control 60 of 92 (65.2%), NNT 3.6.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Koshak et al., 15 Aug 2021, Randomized Controlled Trial, Saudi Arabia, peer-reviewed, 10 authors, trial NCT04401202 (history)
Abstract: Complementary Therapies in Medicine 61 (2021) 102769
Contents lists available at ScienceDirect
Complementary Therapies in Medicine
journal homepage: www.elsevier.com/locate/ctim
Nigella sativa for the treatment of COVID-19: An open-label randomized
controlled clinical trial
Abdulrahman E. Koshak a, *, Emad A. Koshak b, Abdullah F. Mobeireek c, Mazen A. Badawi b,
Siraj O. Wali b, Husam M. Malibary b, Ali F. Atwah d, Meshari M. Alhamdan e, Reem A. Almalki b,
Tariq A. Madani b
Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University 80260, Jeddah, 21589, Saudi Arabia
Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia
University Medical Services Centre, King Abdulaziz University, Jeddah, Saudi Arabia
A R T I C L E I N F O
A B S T R A C T
Background: Effective treatment for Coronavirus Disease-2019 (COVID-19) is under intensive research. Nigella
sativa oil (NSO) is a herbal medicine with antiviral and immunomodulatory activities, and has been recom
mended for the treatment of COVID-19. This study aimed to evaluate the efficacy of NSO treatment in patients
Methods: All adult patients with mild COVID-19 symptoms presented to King Abdulaziz University Hospital,
Jeddah, Saudi Arabia, were recruited for an open label randomized clinical trial (RCT). They were randomly
divided into control or treatment groups, with the latter receiving 500 mg NSO (MARNYS® Cuminmar) twice
daily for 10 days. Symptoms were daily monitored via telecommunication. The primary outcome focused on the
percentage of patients who recovered (symptom-free for 3 days) within 14-days. The trial was registered at
Results: A total of 173 patients were enrolled for RCT. The average age was 36(±11) years, and 53 % of patients
were males. The control and NSO groups included 87 and 86 patients respectively. The percentage of recovered
patients in NSO group (54[62 %]) was significantly higher than that in the control group (31[36 %]; p = 0.001).
The mean duration to recovery was also shorter for patients receiving NSO (10.7 ± 3.2 days) compared with the
control group (12.3 ± 2.8 days); p = 0.001.
Conclusions: NSO supplementation was associated with faster recovery of symptoms than usual care alone for
patients with mild COVID-19 infection. These potential therapeutic benefits require further exploration with
placebo-controlled, double-blinded studies.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.